Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franklin M Chu

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The American Journal of Medicine|February 18, 2006
Pathophysiology of overactive bladderFranklin M Chu, Roger Dmochowski
The American Journal of Medicine|February 18, 2006
Management of overactive bladder and urge urinary incontinence in the elderly patientNurum Erdem, Franklin M Chu
Investigational New Drugs|February 11, 2010
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancerFranklin M Chu, Joel Picus, Paula M Fracasso, et al.
American Journal of Obstetrics and Gynecology|June 23, 2005
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trialFranklin M Chu, Roger R Dmochowski, Daniel J Lama, et al.
The Journal of Urology|August 21, 2002
A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancerFranklin M Chu, Maury Jayson, Martin K Dineen, et al.
Clinical Therapeutics|December 28, 2002
A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancerRamon Perez-Marreno, Franklin M Chu, Donald Gleason, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2015
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancerFranklin M Chu, Oliver Sartor, Leonard Gomella, et al.
Urology|August 2, 2003
An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancerOliver Sartor, Martin K Dineen, Ramon Perez-Marreno, et al.
The American Journal of Medicine|February 18, 2006
Management of incontinence for family practice physiciansJohn P Lavelle, Mickey Karram, Franklin M Chu, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The American Journal of Medicine|February 18, 2006
Pathophysiology of overactive bladderFranklin M Chu, Roger Dmochowski
The American Journal of Medicine|February 18, 2006
Management of overactive bladder and urge urinary incontinence in the elderly patientNurum Erdem, Franklin M Chu
Investigational New Drugs|February 11, 2010
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancerFranklin M Chu, Joel Picus, Paula M Fracasso, et al.
American Journal of Obstetrics and Gynecology|June 23, 2005
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trialFranklin M Chu, Roger R Dmochowski, Daniel J Lama, et al.
The Journal of Urology|August 21, 2002
A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancerFranklin M Chu, Maury Jayson, Martin K Dineen, et al.
Clinical Therapeutics|December 28, 2002
A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancerRamon Perez-Marreno, Franklin M Chu, Donald Gleason, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2015
A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancerFranklin M Chu, Oliver Sartor, Leonard Gomella, et al.
Urology|August 2, 2003
An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancerOliver Sartor, Martin K Dineen, Ramon Perez-Marreno, et al.
The American Journal of Medicine|February 18, 2006
Management of incontinence for family practice physiciansJohn P Lavelle, Mickey Karram, Franklin M Chu, et al.
Pageof 1